Clinical trial participant showed vision improvement from 20/400 to 20/40 Read more…
Net loss of $6.4 M or $0.00 per share Read more…
Q4/12 net loss of $(10.3) M or $(0.01) loss per share Read more…
Agreement resolves all Litigation associated with previously issued Convertible Debentures Read more…
OTC: ACTC entered into a $35M common stock purchase agreement Read more…
Ruling in favor of the government allows NIH funding for embryonic stem cell research to continue Read more…
Loss of $4M or $0.00 per share Read more…
The Data and Safety Monitoring Board (DSMB) has authorized Read more…
In EU Clinical Trial Read more…
SEC complaint claims improperly distributed shares of stock in 2008 and 2009 to pay off debts and raise money Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.